Outcomes of children treated for relapsed or refractory acute lymphoblastic leukemia: A single tertiary care center experience

Documenti analoghi

• Upregulation of the long noncoding RNA GJA9‐MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia
  di: Kamal Shahamiri, et al.
  Pubblicazione: (2024)
• Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
  di: Hannah Goulart, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness of treating childhood acute myeloid leukemia at a tertiary care center in North India
  di: Shyam Srinivasan, et al.
  Pubblicazione: (2024)
• Comment on: Cost‐effectiveness of treating childhood acute myeloid leukemia at a tertiary care center in North India
  di: Manraj Singh Sra, et al.
  Pubblicazione: (2024)
• High throughput screening aids clinical decision‐making in refractory acute myeloid leukaemia
  di: S. J. Jessop, et al.
  Pubblicazione: (2024)